**Core Concept:** In the context of the question, Down syndrome is a genetic disorder characterized by the presence of three copies of chromosome 21. Down syndrome screening tests are usually conducted in the first trimester of pregnancy to assess the risk of Down syndrome. These tests include:

1. **Fetal Nuchal Translucency (NT) Measurement:** The thickness of the fluid layer between the skin and the bone at the back of the baby's neck is measured using ultrasound. A higher than normal nuchal translucency is associated with an increased risk of Down syndrome.
2. **Maternal Age:** The risk of Down syndrome increases with maternal age.
3. **Maternal Serum Biomarkers (Quad Screen Test):** This test measures four specific substances in the mother's blood: alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A. The levels of these substances are measured and combined to calculate the risk of Down syndrome.
4. **Fetal Nuchal Translucency and Maternal Age:** This test combines the results of fetal nuchal translucency measurement and maternal age to estimate the risk of Down syndrome.

**Question:** An HIV positive, 36 years old female on ART (Anti-Retroviral Therapy) is being evaluated for the first-trimester markers of Down syndrome. Which of the following tests would be affected by the presence of HIV or ART?

A. Fetal Nuchal Translucency Measurement
B. Maternal Age
C. Maternal Serum Biomarkers (Quad Screen Test)
D. Combined Test

**Correct Answer:** C. Maternal Serum Biomarkers (Quad Screen Test)

**Why the Correct Answer is Right:** The presence of HIV or ART would not directly affect the measurement of fetal nuchal translucency, maternal age, or the combined test. However, HIV or ART could potentially impact the results of the maternal serum biomarkers (quad screen test). HIV infection can lead to anemia and renal dysfunction, which can affect the levels of the biomarkers in the mother's blood. ART (Anti-Retroviral Therapy) can also impact the levels of these biomarkers, as it may cause renal dysfunction or liver disease, which can affect the concentration of the biomarkers.

**Why Each Wrong Option is Wrong:**

A. Fetal Nuchal Translucency Measurement: This test measures the thickness of the fluid layer between the skin and the bone at the back of the baby's neck. HIV infection or ART does not directly affect this measurement.

B. Maternal Age: The risk of Down syndrome increases with maternal age, regardless of HIV status or ART use.

D. Combined Test: The combined test combines the results of fetal nuchal translucency measurement and maternal serum biomarkers. HIV or ART would not directly impact this test, but indirectly via effects on the biomarkers.

**Clinical Pearl:** HIV-positive pregnant women on ART must be monitored closely for potential ART-related adverse effects on renal function and liver enzymes, which can influence the